A therapist's hands working gently along a client's forearm at Renu

Baseline arm measurements before breast cancer surgery

Both arms measured before surgery makes early lymphedema detectable: a 3% change means nothing without a baseline. Why, how often after, and who does it.

By The Renu lymphatic and massage team · 6 min read

A baseline measurement of both arms before breast cancer surgery is the starting point that makes early lymphedema detectable. Without it, natural differences between your two arms can be mistaken for swelling, or a small real change missed; the National Lymphedema Network notes misdiagnosis rates of up to 60% when no pre-operative baseline exists. The NLN asks that screening begin at that baseline and continue as often as every three months for two years after an axillary dissection, then less often through year five, with a tape measure, a Perometer or bioimpedance all acceptable tools.

Of everything on your pre-surgery list, a tape measure around each arm is probably the least dramatic. It is also one of the few items that changes what happens years from now. Lymphedema is far easier to treat in its first weeks than its first years, and the only way to recognise those first weeks is to know what your arms looked like before anything was done to them.

Why a starting point matters so much

Nobody’s arms are the same size. Your dominant arm is usually larger, and the difference varies from person to person. The National Lymphedema Network (NLN) diagnosis statement puts a number on the consequence: without a pre-operative baseline, misdiagnosis rates can reach 60%, because “arm volume asymmetry often exists preoperatively.” A therapist who meets you for the first time a year after surgery cannot know whether a 1.5 cm difference at the forearm is new or has been there since you were twenty.

The same statement rules out the obvious workaround. Early post-operative measurements “are unreliable as baselines,” because the arm is already affected by the surgery, dressings, reduced movement and the first phase of healing. The baseline has to come before.

This is why the NLN’s 2026 risk-reduction statement says people at risk should be “regularly and longitudinally screened for lymphedema starting at preoperative baseline,” and why its diagnosis paper lists “preoperative baseline measurements” first among the elements of an ideal surveillance program, ahead of follow-up assessments, education and self-monitoring.

The study that showed what a baseline makes possible

In 2008 the journal Cancer published results from a prospective program of 196 women at a US military medical centre. Each had both arms measured before surgery and then every three months afterwards. If the operated arm’s volume rose more than 3% above its own baseline, lymphedema was diagnosed on the spot and a compression garment was worn for four weeks.

Forty-three women reached that trigger. The average time to onset was 6.9 months after surgery, and at that point the affected arm had gained a mean of 83 mL (6.5%), an amount that is invisible to the eye and often to the person. After the short garment course, volume fell by a mean of 48 mL (4.1%), and the reduction held at an average follow-up of 4.8 months. The garment was then used only during strenuous activity, when the arm felt heavy or when swelling was visible, and the women returned to three-monthly measurement.

The authors’ title says it directly: pre-operative assessment “enables the early diagnosis and successful treatment of lymphedema.” A 3% change is meaningless without a starting point; with one, it is a treatable finding.

How often to measure afterwards

The NLN stratifies the schedule by risk, and asks that it be set with a provider who knows lymphedema.

Risk group	NLN screening frequency
High risk (axillary lymph node dissection)	As often as every 3 months for the first 2 years, then less often in years 3 to 5
Lower risk (for example sentinel node biopsy)	Around every 6 months, alongside self-monitoring

The diagnosis paper adds that screening should run “for at least five years,” because the cumulative incidence keeps rising through that period. It also explains why the effort is worth it: without treatment, 39.7% of subclinical lymphedema after axillary dissection, and 11.5% after sentinel biopsy, progressed to clinical lymphedema in the studies it cites, while early intervention programs have brought the incidence of lymphedema down to a range of 7% to 11%.

Measurement is not the whole of screening. The NLN wants each visit to include symptoms and education as well, and states that best practice is “incorporation of objective measurements with symptom report and clinical examination for accurate lymphedema diagnosis, rather than relying on objective measurements alone.” Heaviness, a sense that the arm is larger, or a sense of swelling are to be reported immediately, whatever the tape says.

What a measurement visit involves

A careful baseline takes longer than people expect, because it is a record, not a reading.

Both arms, every time. The comparison is always between your operated arm and your other arm, and between each arm and its own earlier numbers.
Fixed landmarks. The National Cancer Institute describes four points used in sequential tape measurement: the metacarpal-phalangeal joints (the knuckles), the wrist, 10 cm below the lateral epicondyle (the bony point on the outside of the elbow) and 15 cm above it. Other protocols measure at 4 cm or 10 cm intervals along the whole arm and convert the circumferences to a volume with the truncated cone formula. The NLN notes these protocols are not interchangeable, so the same method must be used at every visit.
Same tester where possible. The NLN diagnosis paper observes that inter-rater reliability improves with standardised protocols and consistent testers.
Your history. Which hand is dominant, your weight (because absolute changes are affected by body weight), any prior injury or surgery on either arm, and your current symptoms.
Your weight and symptoms at each follow-up, so a change in the arm can be read against a change in the body.

Tools vary. The NLN accepts tape girth measures converted to volume, optoelectronic volumetry (a Perometer), 3D camera systems and bioimpedance spectroscopy. The 2022 PREVENT trial compared the first and last of these in 879 women: tape measurement triggered an early intervention in 27.5% of participants and bioimpedance in 20.1%, and fewer of the bioimpedance group went on to chronic lymphedema (7.9% versus 19.2%). Our bioimpedance vs tape measure page weighs that trade-off; for the purpose of this page, the point is that both methods depend on a baseline.

Who does the measuring

Your surgical or cancer program comes first. Many breast programs now include a pre-operative measurement and a surveillance pathway, and if yours does, use it: the same equipment, protocol and team over five years is exactly what the NLN asks for. Ask at your pre-admission visit whether your arms will be measured, and request a copy of the numbers for your own file.

If your program does not measure, or if you want a record kept closer to home, a Certified Lymphedema Therapist can take the baseline and the follow-ups. The NLN’s position is that everyone at risk for lymphedema should ideally be evaluated by a certified lymphedema therapist or another professional knowledgeable about lymphedema. At Renu, Meeghan Mackenzie is a Certified Lymphedema Therapist and Certified Compression Fitter; she works with a tape measure and fixed landmarks, and if an early change ever appears, complete decongestive therapy and a compression fitting are available in the same room. Our preparing for surgery guide covers the rest of the pre-operative list.

We do not have bioimpedance equipment, and we do not duplicate a hospital surveillance program that is already running. Where one exists, it leads and we support it.

When to call your surgeon or oncology team

Call the same day if the operated arm, hand or chest becomes red, warm, painful, suddenly swollen, or if you develop a fever or chills. The NLN treats suspected infection in a limb at risk as an urgent medical event, and cellulitis itself causes further lymphatic damage.

Call promptly, within days, if you notice heaviness, tightness, aching, a ring or sleeve that fits differently, or a sense that the arm is larger. These sensations often come before any measurable change, and the NLN asks that they be reported immediately. Bring your baseline numbers to that appointment; they are what turns a worry into a comparison. The early signs of arm lymphedema page lists them in detail, and when to seek medical care covers the broader red flags after surgery.

Questions people ask

Is it too late to get a baseline if my surgery is next week?

No. A baseline taken any time before the operation is what matters, because the National Lymphedema Network considers early post-operative measurements unreliable as a starting point. Ask your surgical program whether they measure; if they do not, a certified lymphedema therapist can take and record both arms before your surgery date.

What exactly is measured at a baseline visit?

Both arms, always. With a tape measure, the National Cancer Institute describes four standard points: the knuckles, the wrist, 10 cm below the outer elbow and 15 cm above it; other protocols measure every 4 cm or 10 cm along the arm and convert the figures to a volume. A good visit also records your symptoms, your dominant hand and anything that already differs between the arms, because the NLN asks that measurements be read alongside symptoms and a clinical examination, not alone.

How much change counts as lymphedema?

It depends on the method and the program. The NLN diagnosis statement treats a relative volume change of 5% to under 10% from baseline as subclinical lymphedema and 10% or more as clinical lymphedema, while an older standard used a 2 cm or 200 mL difference between arms. The 2008 surveillance study acted at a 3% rise. Whatever threshold your program uses, it can only be applied if a baseline exists.

Do I keep measuring if nothing has changed after two years?

Yes, less often. The NLN suggests high-risk screening as frequently as every three months for the first two years, then continued but less frequent screening in years three to five, and its diagnosis paper says surveillance should continue for at least five years because new cases keep appearing through that period. People at lower risk, such as after a sentinel biopsy, may be screened every six months alongside self-monitoring.